According to the new market research report “Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”, published by QYResearch, the global Microphysiological System market size is projected to reach USD 0.72 billion by 2030, at a CAGR of 30.5% during the forecast period.
- Global Microphysiological System MarketSize(US$ Million), 2019-2030
Source: QYResearch, “Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”
- Global Microphysiological System Top26Players Ranking and Market Share (Ranking is based on the revenue of 2023, continually updated)
Source: QYResearch, “Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”
According to QYResearch Top Players Research Center, the global key manufacturers of Microphysiological System include Emulate, Mimetas, InSphero, TissUse, CN Bio, Valo Health (TARA Biosystems), Hesperos, TNO, AxoSim, Newcells Biotech, etc.
In 2023, the global top 10 players had a share approximately 65.0% in terms of revenue.
Market Drivers and Opportunity:
Drug Discovery and Development: One of the primary drivers of the MPS market is the need for more efficient and predictive models for drug discovery and development. Traditional preclinical models, such as animal testing and cell culture assays, often fail to accurately predict human responses to drugs. MPS platforms offer more physiologically relevant models that mimic the structure and function of human organs, allowing for better prediction of drug efficacy, toxicity, and safety profiles.
Reduction in Drug Development Costs and Time: Drug development is a time-consuming and expensive process, with high failure rates in clinical trials. By providing more accurate and predictive models early in the drug development process, MPS technology has the potential to reduce the time and cost associated with drug discovery and development. This can lead to significant cost savings for pharmaceutical companies and accelerate the pace of bringing new drugs to market.
Personalized Medicine and Precision Medicine: The shift towards personalized medicine and precision medicine has increased the demand for patient-specific models that can better predict individual responses to drugs and treatments. MPS platforms allow for the creation of personalized disease models using patient-derived cells, enabling researchers to study disease mechanisms and test potential treatments in a more relevant context.
Advancements in Microfabrication and Biomaterials: Technological advancements in microfabrication techniques and biomaterials have significantly improved the design and functionality of MPS platforms. These advancements have led to the development of more complex and physiologically accurate organ models, with better control over parameters such as cell culture conditions, fluid flow, and biochemical signaling.
Regulatory Support and Validation: Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have recognized the potential of MPS technology to improve the predictivity of preclinical models and reduce reliance on animal testing. Regulatory support and validation of MPS platforms for drug development applications have contributed to the adoption of these systems by pharmaceutical companies and research institutions.
Rising Demand for Alternatives to Animal Testing: There is growing public and regulatory pressure to reduce and replace the use of animals in preclinical testing due to ethical concerns, scientific limitations, and regulatory mandates. MPS technology offers a promising alternative to animal testing by providing more human-relevant models for studying disease biology, drug responses, and toxicology.
Collaborations and Partnerships: Collaboration between academic institutions, pharmaceutical companies, biotechnology firms, and government agencies is driving innovation and commercialization in the MPS market. Collaborative research efforts are focused on developing advanced organ models, standardizing protocols, validating platform performance, and expanding the application areas of MPS technology.
Emerging Applications in Toxicology and Environmental Testing: In addition to drug discovery and development, MPS technology is finding applications in toxicology testing, environmental monitoring, and disease modeling. These applications have the potential to address a wide range of challenges in chemical safety assessment, environmental risk assessment, and understanding the effects of environmental exposures on human health.
Restraint:
Complexity and Technical Challenges: Developing and commercializing microphysiological systems involves complex interdisciplinary approaches that combine biology, engineering, materials science, and microfabrication techniques. Technical challenges related to mimicking the physiological complexity of human organs, integrating multiple cell types, achieving reproducibility, and ensuring long-term viability pose significant hurdles.
Standardization and Validation: Establishing standardized protocols, quality control measures, and validation criteria for microphysiological systems is essential to ensure consistency, reliability, and reproducibility across different platforms and applications. However, the lack of standardized methodologies and regulatory guidelines for MPS devices complicates validation efforts and may impede market acceptance.
Cost and Affordability: The high cost of developing, manufacturing, and operating microphysiological systems presents a barrier to widespread adoption, particularly in academic research settings, small biotech companies, and resource-constrained laboratories. Cost-effective fabrication methods, scalable manufacturing processes, and strategic collaborations are needed to address affordability concerns and expand market access.
Limited Commercialization and Market Penetration: Despite significant advancements in microphysiological system technology, the commercialization and market penetration of MPS devices remain relatively limited. Challenges in translating research prototypes into market-ready products, securing regulatory approvals, navigating reimbursement pathways, and gaining market acceptance hinder commercialization efforts.
Regulatory and Ethical Considerations: Microphysiological systems intended for biomedical research, drug development, and toxicity testing are subject to regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with regulatory requirements for safety, efficacy, and quality assurance poses regulatory hurdles and may delay market entry.
Intellectual Property and Patent Issues: Intellectual property (IP) protection is critical for companies and research institutions involved in developing microphysiological systems. Patenting inventions, securing licensing agreements, and navigating IP landscapes are essential for protecting proprietary technologies, fostering innovation, and avoiding infringement disputes that could hinder market growth.
Interdisciplinary Collaboration and Talent Pool: Successful development and commercialization of microphysiological systems require interdisciplinary collaboration among scientists, engineers, clinicians, regulatory experts, and industry stakeholders. However, bridging disciplinary boundaries, fostering collaborations, and attracting talent with expertise in diverse fields pose organizational and cultural challenges.
Education and Awareness: Increasing awareness and understanding of microphysiological systems among researchers, healthcare professionals, policymakers, and industry stakeholders is essential for driving market adoption and investment. Education initiatives, training programs, scientific conferences, and knowledge-sharing platforms play a crucial role in disseminating information and fostering community engagement.
About The Authors
| Tuo Rui – Lead AuthorEmail: tuorui@qyresearch.com |
About QYResearch
QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 17 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.
QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US) 0086-133 1872 9947(CN)